Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA(2)DS(2)-VASc Score 0-1: A Korean Multi-Center Cohortopen access
- Authors
- Jung, Moonki; Byeon, Kyeongmin; Kang, Ki-Woon; Park, Yae Min; Hwang, You Mi; Lee, Sung Ho; Jin, Eun-Sun; Roh, Seung-Young; Kim, Jin Seok; Ahn, Jinhee; Lee, So-Ryoung; Choi, Eue-Keun; Ahn, Min-Soo; Lee, Eun Mi; Park, Hwan-Cheol; Lee, Ki Hong; Kim, Min; Choi, Joon Hyouk; Ko, Jum Suk; Kim, Jin Bae; Kim, Changsoo; Lip, Gregory Y. H.; Shin, Seung Yong
- Issue Date
- Oct-2022
- Publisher
- YONSEI UNIV COLL MEDICINE
- Keywords
- Atrial fibrillation; risk stratification; stroke; ABCD score
- Citation
- YONSEI MEDICAL JOURNAL, v.63, no.10, pp.892 - 901
- Journal Title
- YONSEI MEDICAL JOURNAL
- Volume
- 63
- Number
- 10
- Start Page
- 892
- End Page
- 901
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87227
- DOI
- 10.3349/ymj.2022.0157
- ISSN
- 0513-5796
- Abstract
- Purpose: Atrial fibrillation (AF) patients with low to intermediate risk, defined as non-gender CHA(2)DS(2)-VASc score of 0-1, are still at risk of stroke. This study verified the usefulness of ABCD score [age (=60 years), B-type natriuretic peptide (BNP) or N-terminal pro-BNP (>= 300 pg/mL), creatinine clearance (<50 mL/min/1.73 m(2)), and dimension of the left atrium (>= 45 mm)] for stroke risk stratification in non-gender CHA(2)DS(2)-VASc score 0-1. Materials and Methods: This multi-center cohort study retrospectively analyzed AF patients with non-gender CHA(2)DS(2)-VASc score 0-1. The primary endpoint was the incidence of stroke with or without antithrombotic therapy (ATT). An ABCD score was validated. Results: Overall, 2694 patients [56.3 +/- 9.5 years; female, 726 (26.9%)] were followed-up for 4.0 +/- 2.8 years. The overall stroke rate was 0.84/100 person-years (P-Y), stratified as follows: 0.46/100 P-Y for an ABCD score of 0; 1.02/100 P-Y for an ABCD score >= 1. The ABCD score was superior to non-gender CHA(2)DS(2)-VASc score in the stroke risk stratification (C-index=0.618, p=0.015; net reclassification improvement=0.576, p=0.040; integrated differential improvement=0.033, p=0.066). ATT was prescribed in 2353 patients (86.5%), and the stroke rate was significantly lower in patients receiving non-vitamin K antagonist oral anticoagulant (NOAC) therapy and an ABCD score >= 1 than in those without ATT (0.44/100 P-Y vs. 1.55/100 P-Y; hazard ratio=0.26, 95% confidence interval 0.11-0.63, p=0.003). Conclusion: The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA(2)DS(2)-VASc score 0-1. Furthermore, NOAC with an ABCD score >= 1 was associated with significantly lower stroke rate in AF patients with non-gender CHA(2)DS(2)-VASc score 0-1.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87227)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.